Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2858 in Advanced Pancreatic Cancer
NCT05193604Phase 1Terminated
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical
- Start
- Mar 2022
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of bemosesuglimab in pancreatic cancer (PC) (3 cohorts), sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical. Primary endpoints: Dose limiting toxicity at 3 weeks, Recommended phase II dose at 3 weeks and 1 more. Started Mar 2022; status: terminated.
02
Drugs
bemosesuglimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05193604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05193604.